Fresh analysis reveals that patients who come off new GLP-1 drugs like Wegovy and Mounjaro tend to recover shed pounds at a significantly accelerated pace than those who end traditional diet and exercise regimens.
Findings released in a major medical journal points out that while obese individuals can lose about a fifth of their total mass while on the medication, the weight is regained at an average rate of nearly a kilo each month once they quit.
"Individuals buying these treatments should be informed of the potential of fast weight regain when the therapy ends," warns researcher Dr. Susan Jebb.
This pace of regain suggests a reversion to starting mass in about 18 months.
Comparing Treatments
The study, which examined dozens of trials involving thousands of patients, compared the effects of these new drugs with older methods.
Researchers emphasize that people who lose weight through dieting typically see a more gradual weight regain—perhaps 100 grams monthly—once they finish.
Understanding the Quick Rebound
Doctors believe the mechanism of the jabs accounts for the amplified weight return.
The injections imitate a body's own chemical called GLP-1, which moderates appetite.
"Long-term administration of GLP-1 concentrations several times higher than normal might result in the body to generate a reduced amount of its endogenous GLP-1, and may also diminish responsiveness to its actions," noted Dr. Adam Collins, a dietetics researcher.
"Discontinuation of this medication results in appetite is no longer kept in check, making overeating a significant risk."
A Chronic Issue?
The NHS advise the jabs for individuals with obesity-related health risks, accompanied by prescribed lifestyle changes.
Many experts say that, given the likelihood of weight regain, the therapy is often long-term.
This perspective is reinforced by drug manufacturers, who state that the findings "emphasize the chronic nature of excess weight," comparing it to managing diseases like diabetes.
Patient Testimonies
Users who have come off the medication describe a intense resurgence of appetite.
"I experienced a trigger activating and you become starving," described a patient.
The struggle is compounded if patients have not developed sustainable dietary or behavioural modifications during treatment.
Growing Adoption
Figures show that a significant number of adults in the UK have used these injections in the past year, with desire remaining high.
- Adoption is more common among females than males.
- The middle-aged age group shows the greatest usage rates.
- Many obtain the drugs through private healthcare rather than the NHS.
Ultimately, clinicians caution that while the jabs are potent agents for weight loss, they are not a permanent cure and lasting health benefits hinges on combined behavioural support.
